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Aim: Delay in the diagnosis of colorectal cancer (CRC) may have important clinical and medico-legal implications.
This study identifies the claims made on the basis of delay in the diagnosis of CRC to the Swedish insurance
agency (whose English name is The County Council´s Mutual Insurance Company) and the impact and
consequences of the delay on prognosis, treatment and survival for patients who reported the claims. The
Company handles claims of medical malpractice where claimants seek compensation for alleged suffering
and/or negative clinical impacts of diagnostic delays.
Material and methods: Between January 1, 1995 and December 31, 2008, a total of 80 patients filed claims for
negative effects resulting from delays in the diagnosis of CRC. Review of the claims led to identification of delay for
62 patients. The clinical symptoms that were overlooked and other causes of delay that had any relation to therapy,
prognosis and economic compensation were evaluated.
Results: The median delay in the diagnosis of CRC was six months. This delay was considered to have had an
impact on the therapy in 20 % of the cases. The prognosis was postulated to have been adversely affected for
15 % of the patients. The delay was mainly caused by incomplete consideration of the symptoms hematoschisis or
anaemia, changed bowel routine, or incomplete clinical or radiological examination and by misinterpretations of
the results. No impact of duration of delay on survival was identified. The importance of identifying concomitant
metastatic disease at diagnosis was overwhelming. Economic compensation was given in 79 % of the cases.
Conclusion: This study found that claims for compensation for delay in diagnosis of CRC are rare. The delay in the
diagnosis of the primary tumour was considered to have had an impact on the magnitude of therapeutic measures
for a fifth of the patients who filed claims. Economic compensation for the patients´ injuries was given in almost
80 % of the cases.
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Health-care related injuries and adverse events are always
harmful for patients. In international analysis the inci-
dence of adverse advents varies between 2.9-16.6 % [1,2].
In a Swedish study it was assessed to be 12.3 % [3]. In
Sweden, with a population of 9.3 million, the official
number of patient injuries exceeds 10,000 per year* Correspondence: lo.hafstrom@surgery.gu.se
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reproduction in any medium, provided the orcorresponding to less than one percent of all hospitaliza-
tions [4]. Among adverse events, doctors’ delay in
diagnosis and management of malignant diseases is well
recognized.
In Sweden colorectal cancer (CRC) is common and
about 6200 individuals annually will get the diagnosis of
CRC. In Sweden there are no available data about the
consequences or impact of delay in diagnosis and treat-
ment of CRC. A delay in the diagnosis of any cancer
causes the patient to believe that she/he has lost
the chance of cure or improvement. There are alsoal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with diagnostic delay. It is also important to
consider any medico-legal implications of health-care
related injuries and adverse events, which in the individ-
ual case can have very serious consequences.
Sweden has had a patient insurance system to com-
pensate patients for health-related injuries since 1975.
Patients who have been treated within the medical ser-
vice system financed by the county medical councils
(Landstinget in Swedish) can report their claims to the
malpractice insurance review board referred to here as
LÖF (Landstingens Ömsesidiga Försäkringsbolag, in
translation to English The County Council´s Mutual In-
surance Company). The patients may request economic
compensation for the suffering and/or negative impacts
on the treatment and the prognosis of the disease they
have experienced. The insurance covers both physical
and psychological injuries. The insurance company LÖF
processes more than 90 % of all patient injury claims,
mainly as a consequence of the county councils being
responsible for almost (more than 90 %) all medical care
in Sweden. In this health-care system it is uncommon
for patients to request a second medical opinion.
The aim of this retrospective study was to identify the
cause of the claims made to LÖF for diagnostic delay of
CRC and to explore the consequences of the claimed
delay on treatment, prognosis and survival. It also identi-
fied the extent to which economic compensation was
given to the claimers.Material and methods
In Sweden (9,300,000 inhabitants) there are annually
6200 individuals who will get the diagnosis of CRC. Be-
tween January 1, 1995 and December 31, 2008 altogether
80 claims to LÖF were identified under the heading
CRC-delayed diagnosis. Nine of the 80 claims could be
excluded as they were related to treatment complica-
tions, six were registered under the wrong heading, and
in three cases no cancer was diagnosed. The remaining
62 claims were recognized as involving delayed diagnosis
and the charts and histopathological reports of these
claims were scrutinized.
The alleged diagnostic delay was calculated in
months from the date given in the patient´s report to
LÖF to the date of clinically established diagnosis of
cancer. Each author judged separately the impact of
delay on prognosis and consequences on therapy with-
out reference to the statements by the reviewers at
LÖF. In the cases where there were differences be-
tween the authors´ judgments the terms supposedly or
probably were added. There was no analysis of the psy-
chological harm the delay could have caused the indi-
vidual patient.Data concerning survival were received from Swedish
Cancer Register. Survival time was calculated from date
of established diagnosis of cancer.Statistics
The survival probability was analyzed using the Kaplan-
Meier method (Stat-viewW 5.0). Anova factorial (Stat-
viewW 5.0) was used for analyzing differences between
groups.Results
It was calculated that LÖF receives 4.4 claims dealing
with CRC annually corresponding to 0.7 per 1000 new
cases of CRC. Between 1995 and 2005 there were 62
claims of diagnostic delay of CRC. In 51 claims there
was a delay in diagnosing the primary tumour and in
two diagnosing recurrent/metastatic disease. In nine
cases the delay was attributed to systemic errors made
by the providers, in 7 delays in remitting the patient to
the X-ray or CRC care unit. In one case the reply from
the X-ray unit disappeared and in one an exchange of X-
ray answers was found. In 34 cases the diagnostic delay
concerned colon cancer, in 27 cases rectal cancer and in
one case the diagnosis was squamous cell cancer. At the
time for diagnosis 11 patients with colon cancer had me-
tastases and in cases with rectal cancer this figure was
12. The two cases with a delay in recognizing recurrent/
metastatic disease were cases of rectal cancer. Of these
23 patients with metastatic disease the grading of the
primary CRC cancer according to the classical Dukes’
method was Dukes’ B in 1, Dukes’ C in 10 and in 12
cases no grading could be identified as no histomorpho-
logical analyses had been performed.
The sex and age distribution in six cohorts of the
claimers on the date of missed diagnosis is depicted in
Table 1. Mean and median age of the patients in the
study was 59 years.
Haematoschisis or anaemia was the predominating
symptom in 33 cases (53 %), changed bowel habits in
six, and pain in five cases. In 14 patients the different
symptoms overlapped (Table 2). In two patients there
was an error in the follow up after curative surgery. Po-
tential causes of claims at the time of missed diagnosis
are shown in Table 3. In most cases clinical symptoms
failed to be recognized by the first doctor seen by the
patient (44/62). In ten cases the diagnostic delay was
due to incomplete clinical examination (colonoscopy,
barium enema, CT). In four cases the delay was due to
radiological error.
Localisation of the cancer in the colon or the rectum
and staging of CRC according to Dukes’ classical criteria
and the duration of diagnostic delay of more or less than
6 months are shown in Table 4.
Table 1 Age distribution and gender for individuals at








≤ 40 1 2 3
41-50 7 4 11
51-60 4 14 18
61-70 13 7 20
71-80 4 4 8
≥ 80 1 1 2
Total 30 32 62
Table 3 Potential causes of diagnostic delay in 62
patients with colorectal cancer
Symptoms No. of patients
Clinical error
Clinical signs were not recognized
44
Delay in appropriate investigation 4
Incomplete clinical examination 10
Radiological error
Misinterpretation of malignant lesion 2
Incomplete X-ray 2
Total 62
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D) at the time of diagnosis. Eleven of these patients had
liver metastases, three lung metastases, one both liver
and lung metastases, two skeleton metastases, one ovar-
ian, one suprarenal and four generalized cancer.
The median alleged delay in diagnosis of CRC was
6.0 months (range 0.7-43). In five claims no delay was
identified and in one the delay was less than one month.
The majority of patients who had a delay of less than
6 months (24/32) were without metastatic disease. For
17 claimants the diagnostic delay was more than one
year, eight of them had metastatic disease. The claimed
diagnostic delay was considered to have had an impact
on the extent of therapy concerning the surgical, radi-
ation or chemotherapeutic procedures in 12 of 60
patients (20 %). Five of these patients had metastases
and eight of them had a delay of more than 6 months
(Table 5).
In seven patients and probably in an additional two, in
total 9 of 62 (15 %) the diagnostic delay was considered
to have had an impact on prognosis. Three of the
patients had metastatic disease at diagnosis. In eight of
these cases the diagnostic delay was more than 6 months
and in one less than 6 months. Of the 29 patients with a
delay of more than 6 months, 8 were considered to haveTable 2 Principal presenting symptom in patients for









Bleeding and/or anaemia 33 6 27
Diarrhoea 6 2 4
Pain 5 1 4
Renal symptoms 1 0 1
Perineal infection 1 0 1
Overlapping symptoms 14 5 9
Recurrent disease 2 0 2
Total 62 14 48experienced a worse prognosis. Of the 31 cases with a
delay of less than 6 months, this figure was one
(p = 0.0158).
The Kaplan-Meier curves showed no significant differ-
ence in survival related to duration of diagnostic delay of
more or less than 6 months (Figure 1) or 12 months.
There was a significant difference in survival (p< 0,0001)
between patients with and without metastatic disease at
diagnosis (Figure 2).
Economic compensation for diagnostic delay was
approved for 49 of 62 patients (79 %). The rules stated
for economic compensation are that there should be a
causal relationship between the claimed injury and the
care and that it could be established that the injury
could have been avoided.
Discussions
This retrospective study identified a low number of
claims for compensation for patients who reported a
diagnostic delay of CRC related to the clinicians (53/62)
or to the providers (9/62). This number covered a period
of 14 years, i.e. approximately five claims annually com-
pared with an overall rate of 6200 new cases of CRC
reported each year to the Swedish Cancer Register. More
than half of the claims (52 %) were reported by patients
younger than 60 years, who account for only 20 % of the
age distribution of patients with CRC. The majorityTable 4 Delay time in relation to type of primary tumour
and staging at diagnosis
Delay time (months) Dukes’ A-B Dukes’ C Dukes’ D Total*
< 6 8 15 8 31
≥ 6 5 9 15 29
Total 13 24 23 60
Delay time (months) Dukes’ A-B Dukes’ C Dukes’ D Total*
< 6 8 15 8 31
≥ 6 5 9 15 29
Total 13 24 23 60
*In one case with more than 6 months´ delay no cancer was found after
preoperative irradiation and one patient had a squamous cell cancer.









Dukes´A or B 1 0 12 13
Dukes´C 6 0 18 24
Metastatic disease
“Dukes´D”
3 2 18 23
Total 10 2 48 60
* In one case no cancer was found after preoperative irradiation and one
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Figure 2 Survival curves (months) for patients without
metastatic disease (black) and with metastatic disease (gray).
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gastrointestinal bleeding or anaemia and in these cases
no diagnostic procedures were carried out or incorrect
procedures were undertaken. At diagnosis more than
one third (37 %) had an advanced cancer with metastatic
disease.
From the present study it is not possible to draw any
conclusion of the total rate of diagnostic delay of CRC
in Sweden. It can only be stated that during the period
studied the malpractice insurance company (LÖF) pro-
cessed about five cases annually dealing with diagnostic
delay of CRC. This may be an underestimate because
some patients may refrain from filing claims. However,
these data correspond rather well with those reported by
the Physician Insurers Association of America (PIAA).
PIAA, which was started in 1985, has received about
2500 colorectal claims between 1985 and 2006; e.g.
about 120 claims per year or one per 1000 new cases of
CRC in clinical care in the US (150.000 new cases are
diagnosed yearly). There was, however, a big difference
between the two insurance systems regarding economic
compensation. In the Swedish system almost 80 % were
compensated, in the US system somewhat more than
25 % [5].
According to Eurocare 4 the 5-year survival is 61.5 %
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Figure 1 Survival curves (months) for patients with less than 6
months delay (black) and more than 6 months (gray).Sweden the relative survival rate is slightly higher for
women than for men, but almost equal for patients if
the tumour is located in the colon compared with that
located in the rectum.
It is a dogma that early diagnosis of cancer before the
onset of symptoms improves survival [7,8]. However, the
importance of delay when symptoms have appeared is
unclear. That was obvious from a meta-analysis includ-
ing 40 studies of CONCORD representing 20,440
patients. Of the 26 studies that were evaluated, 20
showed no association between delay and survival, four
showed that delay contributed to a better prognosis, and
two studies to a poorer prognosis [9]. The results of this
review suggest that there is no clear association between
diagnostic or therapeutic delay and survival in CRC
patients. In contrast with these statements, it was shown
in a Danish study of 740 patients that a total therapeutic
delay of at least 60 days had an impact on long-term
survival on patients with rectal cancer but that there was
no association between delay and mortality for patients
with colonic cancer [10]. It was also apparent from this
study that neither provider delay, nor hospital delay had
any influence on survival; the only factor that had a
negative effect was the total therapeutic delay and that
was restricted to patients with rectal cancer. The obser-
vation that diagnostic delay only relates to rectal cancer
and not to colonic cancer has been described in other
studies [11,12].
This study indicated that the delay of some kind
affected the therapy since the delay resulted in a need
for more extensive surgery or for down-sizing X-ray or
chemotherapy. For patients with metastatic disease 5 out
of 23 were not subjected to liver surgery and/or down-
sizing chemotherapy due to too advanced disease. It was
suggested that the diagnostic delay had an influence on
the prognosis in only 15 % of the patients; all these were
referred to stage Dukes’ C (n = 6) or metastatic disease
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experience of the authors and are open for debate. It
can, however, be considered obvious that diagnostic
delay has a negative influence on a cancer disease but
the analysis made here on the basis of our study pro-
vides support for those who question this statement
[13,14]. It is undebatable that any cancer has the poten-
tial to metastasize before it is clinically detectable [15].
In the present study there was no significant impact
on survival of a delay, whether the delay was more than
6 months or less than 6 months. The most important
impact on survival in this selected group of patients with
CRC was that metastatic disease of any location signifi-
cantly (p< 0,001) reduced survival (Figure 2). These
findings have to be seen against in the context of those
patients who claimed diagnostic delay had metastatic
disease in 37 %.
The relation between diagnostic delay and survival is
complex. Findings that raise questions about standard
cancer kinetics come from studies that have found that
longer delay has resulted in improved survival [14]. The
most common explanation for this observation is that
less aggressive cancers have a longer lead time until they
produce significant symptoms [10]. Cancer-mortality
statistics are used for comparisons but they are influ-
enced by well-known problems of confounding factors
that can explain the varying results [16].
In this study the diagnostic delay was in 71 % of the
cases related to the inability of the doctor who first met
the patient to identify adequate signs of CRC, i.e. bleed-
ing, anaemia and changes in bowel habits. The diagnos-
tic guidelines established in Sweden were clearly not
followed. Colonography or colonoscopy (and biopsy, if
indicated), must be considered as routine examinations
with a diagnostic predictive value of above 90 and 80 %,
respectively [17]. In a few cases the delay was caused by
misinterpretation of X–ray investigations. It is important
to emphasize that when a barium enema is used and is
difficult to interpret, a colonoscopy should always be
performed.
The insurance company (LÖF) showed a generous at-
titude to the claimers, since it is documented that in
79 % of the case the patients were economically com-
pensated. The high rate can be explained by the fact that
LÖF covers injuries where it can be proved that the in-
jury is related to the medical care and could have been
avoided. There are no regulations requiring disciplinary
actions in LÖF´s system but the insurance company is
working on developing objective grounds for determin-
ing the right for the patient to receive compensation
according to the provisions of The Swedish Patient In-
jury Act.
The strength of this analysis is related to the condition
that the data were collected from a well-establishedpatient national insurance system in Sweden covering a
long period (14 years). The information was based both
on the hospitals’ records and on patients´ reports to
LÖF. The survival data were obtained from an authorita-
tive organization on a national basis. The limitations of
this study arise because of the nature of retrospective
analyses associated with sometimes incomplete data and
a limited number of patients. Furthermore, the evalu-
ation of impact concerning prognosis and consequences
of the treatment and course was based on the joint judg-
ments of the authors independent of the primary state-
ments made by the insurance company.
Conclusions
This study indicated that patients with CRC rarely file
claims for economic compensation for diagnostic delay.
The delay of diagnosis was a median of six months and
was mainly the result of clinical errors. The delay was
considered to have had an impact on treatment in a fifth
of the patients who filed claims and the prognosis was
postulated to have been adversely affected in 15 %. No
impact on survival was identified. Economic compensa-
tion was given to the claimers in almost 80 %.
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